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It is half a century since Roy Calne, a transplant surgeon, publishedhis work revealing the distinct nature of immune responses in the
liver.1 These results from studies of ‘Strange English Pigs’, showing
unexpected tolerance, were pivotal in the field.2 Fifty years on, liver
transplantation has moved on enormously but the liver itself remains a
very difficult organ to study. The lessons learned from these landmark
studies have been very influential in other settings (both in health and
disease) and the ‘tolerogenic environment’ of the liver is thought to have a
role in infection, inflammation and cancer. In this special issue, a range of
authors discuss the balance that is struck in the liver between tolerance
and reactivity, and importantly discern the critical cell types and mediators
involved in this complex biology. The anatomical structure of the liver
vasculature allows for constant screening of the blood for systemic and
gut-based pathogens. This vasculature consists of a slow-flowing capillary
network, the sinusoids, which contain unique subsets of immune and
endothelial cells, critical for the liver’s and ultimately the host’s defence.
Thus, understanding liver immunology means exploring and experimen-
tally dissecting this unique microenvironment. This issue covers the key
areas of clinical liver disease and condenses the emerging evidence for the
roles that liver-resident cells have in liver pathology and protection.
The selected reviews emphasize the role of the diverse immune cell
populations present in the liver, with particular focus on mucosal-
associated invariant T (MAIT) cells, monocyte-derived macrophages
and tissue-resident T cells that act in concert with structural cells of
the liver such as liver sinusoidal cells and Kupffer cells. These cell
populations, poised for action, take centre stage in regulating the fine
balance between immediate responses against invading pathogens and
prevention of systemic inflammation and auto-immunity.
In 2010, two seminal papers showed that MR1-restricted
MAIT cells have a potential role in the protective immunity against
various bacteria and yeasts.3,4 MAIT cells were found to be highly
enriched in the human liver and one of the most dominant
lymphocyte types found in both health and disease. Kurioka et al.5
summarise the evidence for the function of this abundant and
distinctive population of hepatic T cells. Based on multiple published
studies, they build the case that liver MAIT cells are one of the critical
players in the first line of defence described as the liver ‘firewall’.6
Another cell type infiltrating the liver, in response to tissue injury, is
the monocyte-derived macrophage. Brempelis et al.7 discuss the dual
role of these cells in non-infectious liver injury, where they promote
inflammation to allow for efficient clearance of damaged tissue,
whereas also stimulating physiological wound healing. As rapid and
effective tissue repair is one of the hallmarks of the liver, the balanced
activities of these cells may be crucial for liver health.
The review by Wohlleber et al.8 emphasizes the role of other liver
sinusoidal cells, specifically liver sinusoidal endothelial cells (LSECs)
and Kupffer cells, in liver-specific pathogen responses. These cells
serve as unique physical platforms for circulating immune cells to be
retained in the liver and enable efficient antigen-specific retention of
effector CD8 T cells. This is likely to be critical in the protection of the
liver from invading pathogens. However, the exact nature of the
interactions of MAIT cells or other innate lymphocytes present in the
liver sinusoids, such as natural killer T (NKT) cells and gamma-delta
T cells, with LSECs and Kupffer cells will require further investigation.
McNamara et al.9 delve deeper into the retention and recruitment
of innate and adaptive lymphocyte populations (NKT, NK, CD8+ and
CD4+ T cells) in the liver. A particular focus of their review is on the
molecular and cellular interactions that allow for the transition of a
circulating cell to a cell that takes up residency in the liver and their
motility within the liver. Modulating these interactions (blocking or
enhancing) may be one way of shifting the balance of the liver
immune system from inflammation to protection.
The reviews by Holz et al.10 and Wong et al.11 both focus on the
critical role of liver-resident CD8+ T cells, one in the context of malarial
infection, the other highlighting their role in tolerance to allografts. The
review by Holz et al. highlights how the liver phase of malarial infection
represents a bottleneck for overt malaria. Emerging evidence suggests
that liver-resident memory CD8+ T cells are particularly effective in
providing protection against the spread of malaria parasites to the blood,
thus holding the promise to be amenable to achieve sterilising immunity.
Wong et al. explain the unexpected role for CD8+ T cells in the
establishment of liver allograft tolerance, adding further molecular and
cellular detail to the phenomenon. Thus, both reviews highlight the
critical roles of liver-resident CD8+ T cells in liver protection.
The final three reviews of this special issue are more clinically
orientated. Ban-Hok Toh12 provides an overview of the diagnostic
antibodies that differentiate the various subtypes of auto-immune liver
disease, emphasising that further definition and stratification of these
pathologies—as well as better understanding of the underlying
immune processes—is needed to bring forward better therapies for
this complex group of severe chronic diseases.
Valaydon et al.13 examine the role of tumor necrosis factor (TNF) in
chronic hepatitis B virus (HBV) infection, a disease claiming over one
million lives per year. Despite our advances in understanding HBV
biology, treatment options are limited and rarely curative. Appro-
priately termed the ‘Jekyll and Hyde’ cytokine, TNF contributes
significantly to viral immune control within in the liver; however, this
may come at the cost of collateral damage of tissue injury and possible
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induction of hepatocellular carcinoma (HCC). Recently, immune
modulation in a mouse model of chronic HBV with antagonists of
cellular inhibitors of apoptosis has shown promising results.
These antagonists augment TNF-mediated apoptosis of virally infected
cells, thus promoting viral clearance while ameliorating tissue damage.
Elsegood et al.14 summarise the latest studies on the treatment of HCC.
With the emergence of cancer immune checkpoint inhibition, significant
advances have been made in cancer therapy. However, data about the use
of these therapies in HCC therapies are just emerging. Given the difference
of liver immunology compared with conventional adaptive responses
outside the liver, immunotherapy against HCC may be not straightforward.
Overall, these reviews highlight the complexity of liver biology in
health and disease. The distinct organisation and composition of the
liver’s immune system has evolved to safeguard this vital organ, which
has unique physiologic roles but also serves as a gateway to systemic
infections. Although the mucosal immune system of the gut and its
associated microbiome has been the subject of an enormous number
of studies, the similarly complex and tightly linked environment of the
liver has received less attention. However, given the new tools and
models described in these reviews, there is reason for optimism. Fifty
years on from Roy Calne and his ‘strange pigs’, the liver still has plenty
to teach us and likely has further surprises in store.
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